酒精性肝炎的当前临床试验与新型治疗靶点
酒精性肝炎是慢加急性肝衰竭的临床综合征,短期死亡风险高,现有治疗欠佳。STOPAH研究结果改进了临床试验设计认识,肝移植数据令人鼓舞但不足2%患者符合条件。肠道菌群、炎症与细胞因子信号、氧化应激与线粒体功能障碍及肝脏再生能力异常等参与病理,本文描述针对这些通路的新型药物及正在进行的临床试验。
要点
- 酒精性肝炎现有治疗欠佳,STOPAH研究结果改进了临床试验设计认识。
- 肝移植数据令人鼓舞,但不足2%的酒精性肝炎患者符合条件。
- 肠道菌群、炎症与细胞因子信号、氧化应激与线粒体功能障碍及肝脏再生能力异常参与病理。
核心结论
- 酒精性肝炎现有治疗欠佳,明确存在改善患者生存的新型治疗需求。
研究设计与样本
- 本文为综述,描述针对酒精性肝炎病理生理各通路的新型治疗药物及正在进行的临床试验。
主要发现
- STOPAH研究结果改进了对如何最好地设计酒精性肝炎临床试验的认识。
- 肝移植治疗酒精性肝炎的数据令人鼓舞,但不足2%的患者符合条件。
- 肠道菌群变化、炎症与细胞因子信号、氧化应激与线粒体功能障碍及肝脏再生能力异常单独或共同参与酒精性肝炎病理。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Alcoholic hepatitis is a clinical syndrome in which patients present with acute-on-chronic liver failure and a high risk of short-term mortality. The current treatment of alcoholic hepatitis is suboptimal. Results recently published from the STOPAH study have improved our understanding of how best to design clinical trials for this condition. Although emerging data on liver transplantation for patients with alcoholic hepatitis are encouraging, less than 2% of these patients qualify. Clearly, there is an unmet need for novel treatments to improve the survival of these patients. Changes in the gut microbiota, inflammatory and cytokine signalling, oxidative stress and mitochondrial dysfunction, and abnormalities in the hepatic regenerative capacity alone or in combination contribute to the pathology of alcoholic hepatitis. In this chapter, we will describe the novel therapeutic agents targeting various pathways in the pathophysiology of alcoholic hepatitis. Specifically, we will describe the ongoing clinical trials in which some of these agents are being studied.
引用
- Singal AK, Shah VH. Current trials and novel therapeutic targets for alcoholic hepatitis. J Hepatol. 2019. PMID: 30658731. doi:10.1016/j.jhep.2018.10.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。